Mycelx Di Share News (MYX)

LONDON MORNING BRIEFING: CRH And TSB Lead Firm Early Market

UK BROKER RATINGS: SocGen Upgrades BT To Buy From Hold

Mycelx To Post Full Year Pretax Loss, Lowers 2015 Revenue Forecast

Sector movers: Oil services bear the brunt of OPEC decision as outlook sours

Oil-related stocks were continuing to feel the impact from a recent plunge in crude prices on Friday, though companies in the energy-services sector were bearing the brunt of the selling pressure. The Organization of Petroleum Exporting Countries (OPEC) decided on Thursday not to scale back their pr

UK BROKER RATINGS: UBS Cuts Whitbread To Sell From Neutral

Mycelx Optimistic On Growing Pipeline Despite Swing To Half Year Loss

Mycelx Wins New Contract With Kuwaiti Petrochemical Company

Monday broker round-up UPDATE

Balfour Beatty: Berenberg lowers target price from 290p to 280p and retains a buy recommendation. UBS lowers target price from 230p to 225p and keeps a neutral rating. Barclays: Citi lowers target price from 305p to 300p and keeps its sell recommendation. Clinigen: Investec cuts target price from

MyCelx Technologies Warns First Half Revenue Hit By Customer Delays

Hutchison China MediPharma director takes stake in company

Edith Shih, a Non-Executive Director and Company Secretary of Hutchison China MediPharma, acquired 20,000 shares in the firm, which is the holding company of a healthcare group based primarily in China and focused on researching, developing, manufacturing and selling pharmaceuticals and health orien